Pubblicazioni scientifiche sui diagnostici non invasivi BioPredictive

Studi sottoposti a revisione paritaria che convalidano i diagnostici ematici BioPredictive per le malattie del fegato — dalle coorti di sviluppo pionieristiche alle meta-analisi a lungo termine.

7/435 Pubblicazioni

NashTest-2 Cancella tutto
  1. An Invisible Early Steatosis Phenotype Defined for a Large Population-Based Cohort.

    Poynard T et al. · Biomedicines · 2025

    FibroTest NashTest-2 SteatoTest-2 Metabolic

  2. Noninvasive, Blood-Based Biomarkers as Screening Tools for Hepatic Fibrosis in People With Type 2 Diabetes.

    Meritsi A et al. · Clin Diabetes · 2022

    ActiTest FibroTest NashTest-2 Metabolic

  3. Prospective external validation of a new non-invasive test for the diagnosis of non-alcoholic steatohepatitis in patients with type 2 diabetes. Key publication

    Poynard T et al. · Aliment Pharmacol Ther · 2021

    FibroTest NashTest-2 SteatoTest Metabolic

  4. Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes.

    Bril F et al. · Diabetes Care · 2020

    FibroTest NashTest-2 Metabolic

  5. Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes. Key publication

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2020

    FibroTest NashTest-2 SteatoTest-2 Metabolic

  6. The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis. Key publication

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2019

    NashTest-2 SteatoTest-2 Metabolic

  7. Impact of steatosis and inflammation definitions on the performance of NASH tests.

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2018

    ActiTest FibroTest NashTest NashTest-2 +3

Mostra l'elenco completo dei risultati. La pagina è renderizzata sul server e non è paginata.